Idexx Laboratories Adjusts Guidance As Q3 Revenue Growth Slows, Analyst Notes Fewer Veterinary Visits, Looks Towards Long-Term Growth
Portfolio Pulse from Vandana Singh
Idexx Laboratories reported a Q3 adjusted EPS of $2.79, beating expectations, but missed revenue estimates with $975.54 million. The company adjusted its full-year revenue guidance downwards due to slower growth from fewer veterinary visits. Despite short-term challenges, long-term growth is expected from increased pet ownership.
October 31, 2024 | 4:55 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Idexx Laboratories reported Q3 EPS of $2.79, beating expectations, but missed revenue estimates. The company adjusted its full-year revenue guidance downwards due to slower growth from fewer veterinary visits. Despite short-term challenges, long-term growth is expected from increased pet ownership.
Idexx Laboratories' Q3 earnings beat expectations, but revenue fell short, leading to a downward adjustment in full-year guidance. The decline in veterinary visits is a short-term challenge, impacting the stock negatively. However, long-term growth prospects remain due to increased pet ownership.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100